Expert opinion on biological therapyHumansAdalimumabBiosimilar PharmaceuticalsArthritisRheumatoid
Clinical and out-of-pocket cost outcomes after switching to biosimilar adalimumab-atto in patients with rheumatoid arthritis.
Antony T-H Lin, Fang Niu, Rita L Hui, Abbey Londa, Catherine Pham, Samantha Teshima, Thomas Delate
Published: 202510.1080/14712598.2025.2574011
Abstract
BACKGROUND: Limited real-world studies have evaluated outcomes after switching treatment from a reference product (RP) to a biosimilar product. The objective of this real-world study was to assess the outcomes of switching from RP adalimumab to biosi…
Preview only. Read the full abstract at the source